Show simple item record

dc.contributor.authorConseil exécutif, 103
dc.coverage.spatialGenèveen
dc.date.accessioned2013-06-02T13:47:24Z
dc.date.available2013-06-02T13:47:24Z
dc.date.issued1999
dc.identifier.govdocEB103.R1
dc.identifier.urihttp://www.who.int/iris/handle/10665/84237
dc.descriptionConseil exécutif, cent troisième session, Point 3 de l’ordre du jouren
dc.description4 p.en
dc.language.isofren
dc.publisherOrganisation mondiale de la Santéen
dc.subjectPharmaceutical productsen
dc.subjectEssential medicinesen
dc.subjectResolutions and decisionsen
dc.subject.meshPharmaceutical Preparationsen
dc.subject.meshDrug Delivery Systemsen
dc.subject.meshDrug Industryen
dc.subject.meshDrugs, Essentialen
dc.titleStratégie pharmaceutique réviséeen
dc.typeGoverning body documentsen
dc.subject.meshqualifierstandardsen
dc.subject.meshqualifierorganization and administrationen
dc.subject.meshqualifierlegislation and jurisprudenceen


Files in this item

Thumbnail

This item appears in the following Collection(‎s)‎

  • EB103
    25 January - 3 February 1999

Show simple item record